Bliss GVS Pharma shares in focus as ESOP Allotment Committee approves allotment of 53,500 equity shares
Why did Bliss GVS Pharma Ltd shares fall today?
On Thursday, October 15, 2026, shares of Bliss GVS Pharma Ltd (BLISSGVS) slipped by 0.78%, closing at ₹655.95. The stock saw mild selling pressure throughout the trading session, ending the day in the red as investor sentiment remained cautious. The decline, though not steep, reflects a broader trend of profit-booking or lukewarm market response to the latest corporate development announced by the company.
In a regulatory filing, the company informed the exchanges that the ESOP Allotment Committee, in its meeting held on October 15, 2026, approved the allotment of 53,500 equity shares of the face value of ₹1 each to eligible employees who exercised their stock options under the Bliss GVS Pharma Limited – Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019). As a result of this allotment, the company's issued, subscribed, and paid-up share capital increased from 10,63,30,473 equity shares (aggregating ₹10,63,30,473) to 10,63,83,972 equity shares (aggregating ₹10,63,83,972).
While ESOP allotments are routine in nature, such share issuances lead to a dilution in earnings per share (EPS), which can put temporary downward pressure on the stock price as the total number of outstanding shares increases. This dilution effect, combined with the fact that newly issued shares can eventually be sold in the open market, may have contributed to the slight decline in Bliss GVS Pharma's share price today. The filing was duly shared with both the National Stock Exchange of India Ltd. (Symbol: BLISSGVS) and BSE Limited (Scrip Code: 506197), with details provided in Annexure-I in accordance with Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
What does Bliss GVS Pharma Ltd do?
Bliss GVS Pharma Limited is a publicly listed pharmaceutical company operating in India, with equity shares listed on both the National Stock Exchange of India Limited (Symbol: BLISSGVS) and BSE Limited (Scrip Code: 506197). The company maintains compliance with SEBI regulations, including the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, reflecting a commitment to sound corporate governance and transparency with its shareholders and regulatory bodies.
The company has an established Employee Stock Option Plan, known as Bliss GVS ESOP-2019, designed to incentivize and retain its workforce by offering eligible employees the opportunity to exercise stock options and hold equity in the company. Following the allotment of 53,500 equity shares to eligible employees, Bliss GVS Pharma's issued, subscribed, and paid-up share capital stands at 10,63,83,972 equity shares of Re. 1/- each, aggregating to Rs. 10,63,83,972/-. The company has structured its share capital with equity shares carrying a face value of Re. 1/- each, and it operates under a well-defined governance framework with dedicated committees, such as the ESOP Allotment Committee, overseeing key corporate decisions.
Bliss GVS Pharma Ltd Financials
In CroresBliss GVS Pharma Ltd reported a revenue of ₹256.99 Crores in March 2026, which increased to ₹285.58 Crores in June 2026, reflecting a sequential quarter-on-quarter growth of approximately 11.1%. The company's profit also showed an upward trend, rising from ₹35.58 Crores in March 2026 to ₹50.1 Crores in June 2026, marking a significant sequential increase of about 40.8%. The sharper growth in profits relative to revenue suggests improving operational efficiency or margin expansion during the quarter. Overall, both revenue and profitability metrics for Bliss GVS Pharma Ltd demonstrated positive growth from March 2026 to June 2026.
Bliss GVS Pharma Ltd Shareholding Pattern
Promoter holding stands at 35.01% of the total share capital. Foreign Institutional Investors (FIIs) hold 8.07% stake in the company, while Domestic Institutional Investors (DIIs) hold 9.46%. Public shareholders hold the remaining 47.45% stake in Bliss GVS Pharma Ltd.
Bliss GVS Pharma Ltd FAQs
Q: Why did Bliss shares fall 0.78% today?
We would like to inform you that the ESOP Allotment Committee at its meeting held today i.e. October 15, 2026 has approved the allotment of 53,500 equity shares of the face value of Re ..... This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Bliss GVS Pharma Ltd?
As per the latest data, promoters hold 35.01% stake in Bliss GVS Pharma Ltd, while FII holding stands at 8.07%. Domestic institutional investors hold 9.46%, and public shareholders account for 47.45% of the equity.
Q: What is the current stock price of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd shares are currently trading at ₹655.95, recording a decline of 0.78% from the previous close.
Q: What is the market capitalization of Bliss GVS Pharma Ltd?
The company currently has a market capitalization of ₹6974.75 crore, reflecting its valuation in the Indian equity market.